MiNA Therapeutics Gains Another Partner in Lilly for its saRNA Technology

By Michelle Liu

Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)

Published: 17 Jun-2021

DOI: 10.3833/pdr.v2021.i6.2612     ISSN: 1756-7874

Section: Research & Development



Expanding its RNA therapeutics portfolio, Eli Lilly has entered into a collaboration agreement with MiNA Therapeutics to develop small activating RNA (saRNA) candidates for up to five targets...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details